

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: 10/562,259
Filing Date: December 21, 2005
Page 3

In the Specification:

Please replace the paragraph beginning at line 14 of page 23 with the following:

Recently approved targeted therapy, gefitinib (~~Iressa~~® IRESSA®, AstraZeneca Pharmaceuticals LP) is now recommended as third-line therapy and as second-line only if the platinum/docetaxel combination was used as first-line therapy.

Please replace the paragraph beginning at line 21 of page 23 with the following:

Chemotherapeutic agents are specified as two-agent regimens for first-line therapy, two agent regimens or single agents for second-line therapy, and one single agent for third-line therapy. Agents used in first- and second-line therapy are: cisplatin (~~Platinol~~® PLATINOL®, Bristol-Myers Squibb Company), carboplatin (~~Paraplatin~~® PARAPLATIN®, Bristol-Myers Squibb Company), paclitaxel (~~Taxel~~® TAXOL®, Bristol-Myers Squibb Company), docetaxel (~~Taxotere~~® TAXOTERE®, Aventis Pharmaceuticals Inc.), vinorelbine (~~Navelbine~~® NAVELBINE®, GlaxoSmithKline), gemcitabine (~~Gemzar~~® GEMZAR®, Eli Lilly and Company), etoposide (~~Toposar~~® TOPOSAR®, Pfizer, Inc.; ~~VePesid~~® VEPESID®, Bristol-Myers Squibb Company; ~~Etopophos~~® ETOPOPHOS®, Bristol-Myers Squibb Company), irinotecan (~~Camptosar~~® CAMPTOSAR®, Pfizer, Inc.), vinblastine (~~Velban~~® VELBAN®, Eli Lilly and Company), mitomycin (~~Mutamyacin~~® MUTAMYCIN®, Bristol-Myers Squibb Company), and ifosfamide (~~Ifex~~® IFEX®, Bristol-Myers Squibb Company).

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: 10/562,259
Filing Date: December 21, 2005
Page 4

Please replace the paragraph beginning at line 8 of page 24 with the following:

Ongoing or recently completed therapeutic trials for various compounds to treat lung cancer include alitretinoin (~~Panretin®~~ PANRETIN®, Ligand Pharmaceuticals), topotecan HCl (~~Hycamtin®~~ HYCAMTIN® GlaxoSmithKline), liposomal ether lipid (Elan Pharmaceutical), cantuzumab mertansine (ImmunoGen), ~~Gavax® (Cell Genesys)~~ oncolytic virus therapy (GAVAX® Cell Genesys), vincristine (~~Onco TCS®~~ ONCO TCS®, Inex Pharmaceuticals), ~~Neovastat® (AEterna Laboratories)~~ a concentrate of shark cartilage (NEOVASTAT® AEterna Laboratories), squalamine (Genaera), mirostipen (Human Genome Sciences Inc.), ~~Advexin® (Introgen Therapeutics)~~ p53 tumor suppressor therapy (ADVEXIN® Introgen Therapeutics), biricodar dicitrate (~~Incel®~~ INCEL®, Vertex Pharmaceuticals), flavopiridol (Aventis), ~~Affintac® (Eli Lilly and Company)~~ pemetrexed (ALIMTA® Eli Lilly and Company), pivaloyloxymethylbutyrate (~~Pivanex®~~ PIVANEX®, Titan Pharmaceuticals), tirapazamine (~~Tirazone®~~ TIRAZONE®, Sanofi-Synthelabo Pharmaceuticals), irinotecan (~~Camptosar®~~ CAMPTOSAR®, Pharmacia), tezacitabine (Chiron), cisplatin/vinblastine/amifostine (MedImmune), paclitaxel/carboplatin/amifostine (MedImmune), ~~Oncomyc-NG® (AVI BioPharma)~~ antisense agent (ONCOMYC-NG® AVI BioPharma), exisulind/vinorelbine (~~Aptosyn®/Navelbine®~~ APTOSYN®/NAVELBINE®, Cell Pathways), tariquidar (QLT), ~~Xyotax® (Cell Therapeutics)~~ paclitaxel poliglumex (XYOTAX® Cell Therapeutics), PEG-camptothecin (~~Prothecan®~~ PROTHECAN®, Enzon), decitabine (SuperGen), ~~Tarceva® (OSI Pharmaceuticals)~~ erlotinib (TARCEVA® OSI Pharmaceuticals), ABX-EGF (Abgenix), ~~Tecosol Paclitaxel® (Sonus~~

Attorney Docket No.: **DEX0491US.NP**
Inventors: **Papkoff et al.**
Serial No.: **10/562,259**
Filing Date: **December 21, 2005**
Page 5

~~Pharmaceuticals)~~ vitamin E-based emulsion formulation of paclitaxel (TOCOSOL PACLITAXEL® Sonus Pharmaceuticals), TheraFab® (Antisoma) a fragment of the mouse antibody HMFG-1 labeled with yttrium 90 (THERAFAB® Antisoma), minodronate (Yamanouchi Pharmaceutical), exisulind/docetaxel/carboplatin (Aptosyn®/Taxotere®/Paraplatin® APTOSYN®/TAXOTERE®/PARAPLATIN®, Cell Pathways), exisulind/gemcitabine HCl (Aptosyn®/Gemzar® APTOSYN®/GEMZAR®, Cell Pathways), IMC-C225/carboplatin/paclitaxel (Erbix®/carboplatin®/paclitaxel® ERBITUX®/CARBOPLATIN®/PACLITAXEL®, ImClone Systems), and vinorelbine (Navelbine® NAVELBINE®, GlaxoSmithKline).

Please replace Table 10 at page 149 with the following:

Table 10: ATCC deposits

Hybridoma	ATCC Accession No.	Deposit Date
Pro104.C55.1	PTA-5277	23 June 2003
Pro104.C25.1	PTA-6076	15 June 24 2004
Pro104.D9.1	PTA-6077	15 June 24 2004
Pro104.K81.15	PTA-6078	15 June 24 2004